Annual Report 2002 - Roche
Annual Report 2002 - Roche
Annual Report 2002 - Roche
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Group figures<br />
Net income in millions of CHF Net income per share and EBITDA<br />
in millions of CHF<br />
non-voting equity security<br />
in CHF<br />
7,000<br />
6,000<br />
5,000<br />
4,000<br />
3,000<br />
7<br />
6<br />
5<br />
4<br />
3<br />
7,000<br />
6,000<br />
5,000<br />
4,000<br />
3,000<br />
2,000<br />
2<br />
2,000<br />
1,000<br />
1<br />
1,000<br />
4,392<br />
4,401<br />
14<br />
5,0<br />
4,562<br />
3,808<br />
0 0 0<br />
| 98 | 99 | 00 | 01 | 02 | 98 | 99 | 00 | 01 | 02<br />
5.09<br />
5.10<br />
5.96<br />
5.38<br />
4.49<br />
6,423<br />
6,647<br />
7,068<br />
7,211<br />
| 98 | 99 | 00 | 01 | 02<br />
7,721<br />
Operating profit in millions of CHF Research and development in millions of CHF Additions to property,<br />
plant and equipment<br />
in millions of CHF<br />
7,000<br />
6,000<br />
5,000<br />
4,000<br />
3,000<br />
2,000<br />
1,000<br />
0<br />
4,350<br />
4,094<br />
4,301<br />
4,438<br />
4,965<br />
3,408<br />
3,732<br />
| 98 | 99 | 00 | 01 | 02 | 98 | 99 | 00 | 01 | 02 | 98 | 99 | 00 | 01 | 02<br />
3,919<br />
3,771<br />
4,132<br />
1,883<br />
1,985<br />
2,115<br />
1,647<br />
1,746<br />
1999–<strong>2002</strong> figures on an adjusted basis; figures are not fully comparable due to Givaudan<br />
spin-off, Vitamins and Fine Chemicals demerger, Genentech transactions and accounting policy<br />
changes.<br />
All per share information in 2001 is restated for the 100 for 1 share split that took place on<br />
4 May 2001.
Change language